Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Enhancing Familial Hypercholesterolemia Detection in South Korea: A Targeted Screening Approach Integrating National Program and Genetic Cascade Screening

  • Jung-Ho Yang (Chonnam National University Hospital Cardio-Cerebrovascular Center) ;
  • Kyung Hoon Cho (Chonnam National University Hospital Cardio-Cerebrovascular Center) ;
  • Young Joon Hong (Chonnam National University Hospital Cardio-Cerebrovascular Center) ;
  • Ju Han Kim (Chonnam National University Hospital Cardio-Cerebrovascular Center) ;
  • Hye-Yeon Kim (Department of Preventive Medicine, Chonnam National University Medical School) ;
  • Min-Ho Shin (Chonnam National University Hospital Cardio-Cerebrovascular Center)
  • Received : 2024.03.25
  • Accepted : 2024.06.12
  • Published : 2024.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Objectives: Familial hypercholesterolemia (FH) increases the risk of premature cardiovascular disease through disrupted low-density lipoprotein cholesterol (LDL-C) metabolism. Although FH is a severe condition, it remains widely underdiagnosed, which can be attributed to barriers in genetic testing and a lack of awareness. This study aims to propose and evaluate a targeted screening program for FH in South Korea by integrating the General Health Screening Program (GHSP) with cascade genetic screening. Methods: The study included individuals with LDL-C levels ≥190 mg/dL identified during the 2021 GHSP (primary participants). Data on demographics, lifestyle, medical history, and family history were collected through questionnaires. Targeted next-generation sequencing was used to identify pathogenic mutations in the PCSK9, APOB, LDLRAP1, and LDLR genes associated with FH. Pathogenic mutations found in primary participants were confirmed in their relatives (secondary participants) using Sanger sequencing. Participant characteristics were analyzed based on the presence of pathogenic mutations. Results: Among 83 individuals with severe hypercholesterolemia identified through the GHSP, 7 primary participants (8.4%) carried pathogenic mutations in the LDLR and PCSK9 genes. In secondary participants, pathogenic mutations were identified in 61.1% of the relatives of 4 patients with pathogenic mutations. The prevalence of pathogenic mutations was significantly higher in primary participants compared to secondary participants. Conclusions: Integrating community resources with FH screening can enhance the early detection and treatment of FH. By utilizing GHSP data and adding genetic screening, the proposed model provides a strategy to reduce the cardiovascular risks associated with FH, supporting its wider adoption at the national level.

Keywords

Acknowledgement

The Korean National Health Insurance Service Gwangju-Jeolla-Jeju regional Office supported in recruiting participants.

References

  1. Authors/Task Force MembersESC Committee for Practice Guidelines (CPG)ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014
  2. Lee CJ, Yoon M, Kang HJ, et al. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. Korean J Med 2022;97:339-52. https://doi.org/10.3904/kjm.2022.97.6.339
  3. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893-6. https://doi.org/10.1136/bmj.303.6807.893
  4. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-90. https://doi.org/10.1093/eurheartj/eht273
  5. Tandirerung FJ. The clinical importance of differentiating monogenic familial hypercholesterolemia from polygenic hypercholesterolemia. Curr Cardiol Rep 2022;24:1669-77. https://doi.org/10.1007/s11886-022-01783-5
  6. Medeiros AM, Bourbon M. Genetic testing in familial hypercholesterolemia: is it for everyone? Curr Atheroscler Rep 2023;25:127-32. https://doi.org/10.1007/s11883-023-01091-5
  7. National Institute for Health and Care Excellence. Familial hypercholesterolaemia: identification and management. London: National Institute for Health and Care Excellence; 2019. 
  8. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-88. https://doi.org/10.1093/eurheartj/ehz455
  9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2019;73:3168-209. https://doi.org/10.1016/j.jacc.2018.11.002
  10. Kim HN, Kweon SS, Shin MH. Detection of familial hypercholesterolemia using next generation sequencing in two population-based cohorts. Chonnam Med J 2018;54:31-5. https://doi.org/10.4068/cmj.2018.54.1.31
  11. Alonso R, Perez de Isla L, Muniz-Grijalvo O, Mata P. Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc Health Risk Manag 2020;16:11-25. https://doi.org/10.2147/VHRM.S192401
  12. Shin DW, Cho J, Park JH, Cho B. National general health screening program in Korea: history, current status, and future direction. Precis Future Med 2022;6:9-31. https://doi.org/10.23838/pfm.2021.00135
  13. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 2020;75:2553-66.
  14. Knowles JW, Rader DJ, Khoury MJ. Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA 2017;318:381-2. https://doi.org/10.1001/jama.2017.8543
  15. Oh K, Kim Y, Kweon S, et al. Korea National Health and Nutrition Examination Survey, 20th anniversary: accomplishments and future directions. Epidemiol Health 2021;43:e2021025.
  16. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24. https://doi.org/10.1038/gim.2015.30
  17. Chora JR, Iacocca MA, Tichy L, et al. The clinical genome resource (ClinGen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med 2022;24:293-306. https://doi.org/10.1016/j.gim.2021.09.012
  18. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9. https://doi.org/10.1038/nmeth0410-248
  19. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-81. https://doi.org/10.1038/nprot.2009.86
  20. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010;7:575-6. https://doi.org/10.1038/nmeth0810-575
  21. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004;25:49-68.
  22. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc 2019;8:e013225.
  23. Jin ES, Shim JS, Kim SE, et al. Dyslipidemia fact sheet in South Korea, 2022. J Lipid Atheroscler 2023;12:237-51. https://doi.org/10.12997/jla.2023.12.3.237
  24. Koyama S, Ito K, Terao C, et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat Genet 2020;52:1169-77. https://doi.org/10.1038/s41588-020-0705-3
  25. Moon S, Kim YJ, Han S, et al. The Korea biobank array: design and identification of coding variants associated with blood biochemical traits. Sci Rep 2019;9:1382.
  26. Srinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC. Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur J Hum Genet 2020;28:1631-44. https://doi.org/10.1038/s41431-020-00725-5
  27. Civeira F, Castillo S, Alonso R, et al. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol 2005;25:1960-5. https://doi.org/10.1161/01.ATV.0000177811.14176.2b